Risultati per: Potenziale terapia per il cancro del colon metastatico

Per le forme con mutazione dei geni Brca. Cala del 42% il rischio recidiva

Il nuovo farmaco Casgevy è prodotto da Vertex Pharmaceuticals Ltd. e CRISPR Therapeutics. Fino ad oggi, il trapianto di midollo osseo, procedura estremamente faticosa che comporta effetti collaterali molto spiacevoli, è stato l’unico trattamento di lunga durata per la talassemia

Sperimentazione dell’Aou “G. Martino” di Messina

Ogni aumento di 260grammi nei consumi giornalieri +9% di rischio

La conferma da uno studio svolto in Finlandia

Circulation, Volume 148, Issue Suppl_1, Page A14540-A14540, November 6, 2023. Introduction:Cardiovascular disease (CVD) and cancer share a common risk factor: chronic toxic stress/allostatic load (AL). Our previous research found that a 1-point increase in AL is linked to a 25-30% higher risk of major cardiac events (MACE) in prostate cancer patients.Hypothesis:Higher AL is associated with increased MACE risk in patients with breast, lung, and colon cancer.Methods:Patients ≥18 years diagnosed for the first time with the mentioned 3 cancers of interest between 2010-2019 at a large, hybrid academic-community practice were included in this retrospective cohort study. AL was modeled as an ordinal measure (0-11;Table 1). Adjusted Fine-Gray Cox proportional hazard regressions estimated the impact of AL pre- and 60 days post- cancer diagnosis on 2-year MACE.Results:Demographic characteristics are summarized in Table 1. Two-year mace MACE occurred in 12.3%, 23.3%, and 9.7% of breast, lung, and colon cancer patients, respectively. Heart failure was the most common MACE, observed in 7.9%, 14.4%, and 4.8% of breast, lung, and colon cancer patients, respectively. Before cancer diagnosis, a 1-point increase in AL raised MACE risk by 11% (aHR=1.11, 95% CI 1.07-1.16) in breast cancer, 18% (aHR=1.18, 95% CI 1.11-1.25) in lung cancer, and 9% (aHR=1.09, 95% CI 1.01-1.18) in colon cancer. After cancer diagnosis, a 1-point increase in AL increased MACE risk by 10% (aHR=1.10, 95% CI 1.06-1.15) in breast cancer and 19% (aHR=1.19, 95% CI 1.12-1.25) in lung cancer, but was not statistically significant in colon cancer (aHR=1.07, 95% CI 0.99-1.16).Conclusion(s):Higher AL levels prior to breast, lung, and colon cancer diagnoses are associated with increased MACE risk. Thus, effective implementation of patient-centered communication considering stress levels, stressors, and coping mechanisms is necessary during cardiovascular screening for these cancer patients. Further prospective studies are needed.

A crescere di più sono le spese a carico di malati e famiglie

The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update (CPU) is to review the available evidence and provide expert commentary on the current landscape of artificial intelligence in the evaluation and management of colorectal polyps.